Kornimate/medical-research-clean huggingface dataset:
evaluation of benztropine for cocaine craving - 2

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to compare the efficacy of benztropine (or da reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.


Eligibility criteria:
please contact site for information.
identifying coping strategies of patients with cancerous wound after a specific nursing accompaniment

Conditions: Cancerous Wounds

Summary: this is a first care research focuses on the study of adaptation strategies implemented by cancerous wound patients. today, advances in treatment generally increases the life expectancy of a patient with cancer. the patients thus live longer with their wound. how to live then? the literature review shows that there is research on adaptation strategies in cancer pathology and that different factors seem to interact with these strategies. however the investigators have not found written on the theme cancerous wound and adaptation strategies. the investigators conducted a pilot study of this research in medical oncology, prof. service duffaud chu timone, which allowed us to highlight patient adherence and motivation centers contacted but also areas for improvement. indeed, the investigators now were doing a study of adaptation strategies implemented by the patient time t of his life. however, adaptation is a process in constant motion, the investigators want to identify two different time patients coping strategies following a specific charge nurse taking.


Eligibility criteria:
inclusion criteria: * adult patient * patient having at least a cancerous wound. * patient having read the information leaflet and has given its consent. * patient able to meet a french language questionnaire. exclusion criteria: * history or active psychiatric illness. * unable to give informed consent. * inability to comply with the protocol procedures for geographical, social or psychological.
an observational study of tarceva (erlotinib) in participants with locally advanced or metastatic adenocarcinoma non-small cell lung cancer (element)

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this multicenter, observational study will evaluate the efficacy and safety of tarceva (erlotinib) in participants with locally advanced or metastatic adenocarcinoma non-small cell lung cancer and an ecog performance status of 0-1. eligible participants receiving tarceva according to the summary of product characteristics and local label will be followed for the duration of their treatment.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * histologically or cytologically confirmed, locally advanced (stage iiib) or metastatic (stage iv) adenocarcinoma non-small cell lung cancer * eastern cooperative oncology group (ecog) performance status 0-1 * adequate hematologic, renal and liver function * participant initiating treatment with tarceva according to the summary of product characteristics exclusion criteria: * any contraindications to treatment with tarceva according to the summary of product characteristics and local label * any other malignancies within the previous 5 years, except for in situ carcinoma of the cervix and basal and squamous cell carcinoma of the skin * previous systemic anti-cancer treatment with her1/egfr inhibitor
study of nivolumab in patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) that have either failed or are not eligible for autologous stem cell transplant (checkmate 139)

Conditions: Lymphoma. Non-Hodgkin

Summary: the purpose of this study is to determine whether nivolumab is effective in the treatment of dlbcl in patients that have failed or are ineligible for asct


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * confirmation of relapsed or refractory dlbcl or transformed lymphoma (tl) * eastern cooperative oncology group (ecog) performance status of 0 -1 * at least one lesion that measures \>1.5 cm * prior therapy and screening lab criteria must be met * appropriate contraceptive measures must be taken exclusion criteria: * known central nervous system (cns) lymphoma * history of interstitial lung disease, prior malignancy, active autoimmune disease, positive test for hepatitis b or hepatitis c virus * prior allogeneic stem cell transplant (sct), chest radiation ≤ 24 weeks from study drug, ≥1000 mg of carmustine bis-chloroethylnitrosourea (bcnu) as part of pre-transplant conditioning regimen, prior treatment with drug targeting t-cell costimulation or immune checkpoint pathways * women who are breastfeeding or pregnant
short-term prednisone to treat sta study(sptss)

Conditions: Subacute Thyroiditis

Summary: efficiency and safety study of short-term prednisone to treat moderate and severe subacute thyroiditis the investigators hypothesize that less adverse reactions will be observed, comparing with the guidelines recommend. the recurrence rate, adrenal insufficiency, temporary and permanent hypothyroidism aren't significant difference.

comparing with the guidelines recommend, short-term (one week)prednisone and nsaids following up next week to treat moderate and severe subacute thyroiditis will be assessed. the patients in wards will be assessed from temperature,erythrocyte sedimentation rate,c-reactive protein,local pain and goiter.the random treatment will be executed in moderate and severe sat after informed consent be signed. subjects will be monitored once every 2 weeks.if patients complained of pain in their neck or if the erythrocyte sedimentation rate is still high,after discontinuation of prednisone, prednisone treatment will be resumed in moderate and severe subject and non-steroidal anti-inflammatory drugs will be used in mild subject.anti-ulcer drugs will be administered to all patients. the endpoint of the study are efficiency and safety of short-term prednisone treating. the investigators will assess adrenal insufficiency (such as anorexia, nausea, vomiting, abdominal pain),steroid withdrawal syndrome, recurrence rate and hypothyroidism. the investigators will observe erythrocyte sedimentation rate,pain,steroid level and thyroid function.

Eligibility criteria:
inclusion criteria: * 18-70 years patients with moderate and severe subacute thyroiditis exclusion criteria: * adrenal cortical dysfunction, * use of corticosteroids in nearly three months, * mild subacute thyroiditis, * non-onset sta, * family history of diabetes, * gastric ulcer, * the special medication history, * heart，liver and renal insufficiency, * tumors, * tuberculosis and * poor compliance.

Keywords: efficacy safety short term subacute thyroiditis
effect of early administration of txa in adult hip fractures

Conditions: Postoperative Blood Loss

Summary: this is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a level ii trauma center. it is well established in the orthopedic literature that tranexamic acid (txa) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. a typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram iv infused prior to incision followed by 1 gram iv infused at the time of wound closure.


Eligibility criteria:
inclusion criteria: * 1. all adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation exclusion criteria: 1. polytrauma patients 2. previous operation on the ipsilateral hip 3. patients with coagulopathies (factor v leiden, sickle cell anemia, etc.) 4. patients with \< 6-month history of thromboembolic event (dvt/pe), stroke, cardiac stents, or myocardial infarction (mi) 5. history of seizure disorder 6. patients on birth control 7. pregnant women 8. prisoners 9. active thromboembolic disease (dvt/pe, mi, stroke)
m5 vs. m6 comparison study with a sub study into the dielectric constant of aspirated cyst fluid

Conditions: Breast Cyst; Breast Cancer Female

Summary: the maria breast imaging system is a conformité européenne (ce)-marked radio-frequency (rf) medical imaging device. the system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues. the performance and imaging characteristic differences between the m5 and m6 versions of maria are not yet well demonstrated in the clinical environment, particularly with regards to cysts. the evaluation of some aspects of this potentially important new technology will occur in this comparative technical study. further, the dielectric constant of cyst fluid is currently not well understood and obtaining readings from aspirated cyst fluid in applicable patients will be attempted.


Eligibility criteria:
inclusion criteria: * attending a symptomatic breast care clinic at the study site * have a palpable lump in the breast * female sex * 18 years or older * able to provide informed consent * not in any identified vulnerable group exclusion criteria: * unable to mount maria patient bed using provided 2-step * unable to lie in the prone position for a period of up to 15 minutes * patient who have undergone biopsy less than 5 days before the maria scan * patient with implanted electronics * patient with breast implants * patients with nipple piercings (unless they are removed prior to the maria scan) * breast size too small or too large to be suitable for both arrays further: * participants with a large cyst or cysts that require draining at their clinical appointment will not be eligible for arm 1, as the procedure to drain their cyst will change the appearance of the cyst from the imaging that they have done that day to the maria image obtained around 10 days later * arm 1 and 2 are mutually exclusive

Keywords: breast cancer breast cancer imaging
fenofibrate in patients with cervical intraepithelial neoplasia and invasive cervical carcinoma

Conditions: Cervical Intraepithelial Neoplasia; Invasive Cervical Cancer

Summary: normally, p53 helps prevent tumors from forming in the body. early studies have shown that fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of hpv-positive tumors in a way that stops the growth of tumors. the purpose of this study is to understand how fenofibrate can be used to treat hpv-positive cervical cancers and cervical dysplasia. researchers will examine collected tissue samples and investigate various genes and proteins to see whether fenofibrate has an effect on hpv-positive cervical cancers and cervical dysplasia.


Eligibility criteria:
inclusion criteria: * participants must have histologically or cytologic confirmed high grade dysplasia or cervical cancer. histologic types include squamous cell, adenocarcinoma or adenosquamous cell carcinoma. * participants must be eligible for surgical management with leep, ckc or hysterectomy or chemoradiation * age ≥ 18 years * normal liver function (ast, alt, bilirubin within institutional normal limits). * participants must be english speaking * participants must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * participants with active liver disease, including primary biliary cirrhosis and unexplained, liver function abnormality * participants with severe kidney impairment (crcl ≤30 ml/min calculated using cockcroft-gault), or end-stage kidney disease on dialysis * participants with preexisting gallbladder disease including active gallstones * known hypersensitivity to fenofibrate or fenofibric acid * participants that are pregnant or breast feeding due to unknown risk to developing fetus/infant. please note: participants of child-bearing potential (have had menses within the past year or have not had total hysterectomy) are actively screened for pregnancy prior to diagnostic procedures and screened again prior to treatment.

Keywords: fenofibrate
new jersey healthcare essential worker outreach and education study - testing overlooked occupations

Conditions: Covid19; Health Care Seeking Behavior; Health Behavior

Summary: this mixed methods study evaluates the effectiveness and cost of a healthcare worker focused outreach intervention strategy versus community organization led outreach to explore contextual factors (individual, family, and community) affecting covid-19 testing implementation outcomes and scalability.

in aim 2, the investigators conduct a mixed methods study to evaluate the effectiveness and cost of: (1) the healthcare worker focused outreach intervention strategy versus (2) community organization led outreach working with community based organizations. the investigators explore contextual factors (individual, family, and community) affecting covid-19 testing implementation outcomes and scalability. the primary outcome is uptake of covid-19 testing using the novel rutgers clinical genomics laboratory/rucdr saliva test, the first fda authorized diagnostic test using saliva to detect sars-cov-2 for non-invasive, home based self-testing. to compare participation rates in the two arms, our primary outcome, the investigators will use data on the number of tests performed per month up to a 12 month study period. for each intervention, the start time is the date of first attempted contact with potential participants and the end date is either the end of the study period, or the date at which the 1000th individual was tested (whichever comes first).

Eligibility criteria:
inclusion criteria for community members and healthcare workers * self-identification as black or hispanic/latino. * resident of union, passaic, middlesex, or essex county, nj. * parent/legal guardian able to provide permission to participate for those under 18 exclusion criteria: * under 4 years of age. * unable to speak, understand, and/or read english or spanish. * unable to provide informed consent/assent
an observational study on the correlation between time of initiation of avastin (bevacizumab) treatment and progression-free survival in patients with metastatic breast cancer (cronos 2)

Conditions: Breast Cancer

Summary: this single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. patients will be followed for up to 12 months after progressive disease occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * previously untreated metastatic breast cancer * scheduled to start 1st line chemotherapeutic treatment * ecog performance status 0-1 exclusion criteria: * any conditions included in contraindication list for avastin * prior chemotherapy for metastatic breast cancer * adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic malignancy completed \<6 months prior to treatment start
clear care® plus vs. peroxiclear™

Conditions: Refractive Error

Summary: the purpose of this study is to evaluate clear care® plus compared to peroxiclear™ for mean residual peroxide in used lens cases collected at day 30 after neutralization at recommended storage time.

participants will wear habitual lenses on a daily wear basis and use the assigned test solution for daily lens care.

Eligibility criteria:
inclusion criteria: * sign informed consent form; * adapted, 2-week/monthly replacement silicone hydrogel contact lens wearers (at least 2 months); * willing to wear study lenses daily wear only on a daily basis (7 days per week and at least 4 hours per day) and attend all study visits; * symptoms of contact lens related dryness as defined by the symptomatic pre-screening questionnaire; * other protocol-specified inclusion criteria may apply. exclusion criteria: * current hydrogen peroxide-based solution user; * routinely sleeps in lenses at least 1 night per week over the last 3 months prior to enrollment; * ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear; * any systemic diseases that may affect the eye or be exacerbated by use of contact lenses or contact lens solutions or which could prevent wearing lenses at least 4 hours per day; * use of systemic or ocular medications for which contact lens wear could be contraindicated; * monocular (only 1 eye with functional vision) or fit with only 1 lens; * history of herpetic keratitis, ocular surgery, or irregular cornea; * other protocol-specified exclusion criteria may apply.

Keywords: contact lens solution
effects of us-guided sapb during breast surgery

Conditions: Hemodynamic Instability; Opioid Use; Block; Breast Cancer

Summary: the serratus anterior plan (sap) block is a technique that has recently gained popularity in the context of breast surgery. sap block resulted in better hemodynamic stability, early ambulation and shorter hospital stay, as well as hospital costs for postoperative breast patients. we aimed to investigate the effects of the serratus anterior plane block in women undergoing breast surgery, in the intraoperative period.


Eligibility criteria:
inclusion criteria: * between the ages of 18-75, * asa i-ii-iii risk group * patients who underwent breast surgery under general anesthesia, who underwent serratus anterior plan block for analgesia, or who were provided analgesia with conventional methods * patients whose informed consent was read and whose consent was obtained exclusion criteria: * who do not want to participate in the study, * asa iv-v patients

Keywords: hemodynamics serratus anterior plane block opioid consumption breast surgery
patienthèque of finisterian (south of brittany) children with cystic fibrosis in the time of precision medicine

Conditions: Cystic Fibrosis

Summary: the objective of this study is to evaluate the relevance of porphyromonas as a biomarker predicting the risk of p. aeruginosa primocolonization in children form 0 to 18 years old with cystic fibrosis.

this is a monocentric study in 3 phases: * pre-inclusion: at the first visit to the crcm (support for a positive screening confirmed by sweat test and genotyping cftr) * inclusion: possible between the 2nd visit to the crcm (about 2 months old) and the 6th month * follow-up: up to 36 months old. the pace of visits will be based on the usual follow-up rate of cf infants clinical and paraclinical data and samples will be collected as part of the usual follow-up of cf children. inclusions and follow-up visits will be carried out at the roscoff crcm as well as respiratory explorations and biological samples. dermatological and odontological follow-ups will be scheduled for each patient at the rate of an annual visit to the chru in brest in the relevant departments.

Eligibility criteria:
inclusion criteria: * newly screened infants with a confirmed diagnosis of cystic fibrosis in its classic form (clinical symptoms and two positive sweat tests and/or two mutations of the cftr gene from class i to iii) * children free of any colonization with p. aeruginosa * affiliation with the social security system * consent signed by the holders of parental authority or the sole parent holding parental authority exclusion criteria: * children colonized with p. aeruginosa according to the cytobacteriological examination and / or molecular test of sputum or pharyngeal specimens * children grafted * children not affiliated to a social security scheme or not entitled to * children whose parent (s) are (are) minor (s) * children whose holders of parental authority do not master the french language * refusal to participate in the study
perioperative risk calculator

Conditions: Perioperative/Postoperative Complications

Summary: the aim of this project is to develop a machine-learning model for calculating the risk of postoperative complications. in addition to the data collected during the premedication, the model will include all intraoperative values recorded in the patient data management system (pdms), which include not only vital and respiratory parameters, but also medication and doses, intraoperative events and times. postoperative complications are defined according to their severity according to the clavien-dindo score (dindo, demartines et al., 2004) and are collected from the data available in the health information system (his). the machine-learning model is created using an extreme-gradient boosting algorithm which has been updated with new data from the year 2021 to ensure accuracy of the model.


Eligibility criteria:
inclusion criteria: * all patients who underwent surgery with anesthesia exclusion criteria: * none

Keywords: machine learning decision support risk calculator anesthesia
phase 3 study of plozasiran in adults with hypertriglyceridemia

Conditions: Hypertriglyceridemia

Summary: this phase 3 study will evaluate the safety and efficacy of plozasiran injection (aro-apoc3) in adult participants with hypertriglyceridemia (htg). after providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.


Eligibility criteria:
inclusion criteria: * established diagnosis of hypertriglyceridemia (htg) and prior documented evidence (medical history) of mean fasting tg level ≥150 mg/dl (≥1.69 mm/l) and ≤499 mg/dl (≤5.64 mmol/l) * mean fasting tg level ≥150 mg/dl (≥1.69 mmol/l) and ≤499 mg/dl (≤5.64 mmol/l) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period * fasting low density lipoprotein-cholesterol (ldl-c) ≤ 130 mg/dl (≤3.37 mmol/l) at screening * screening hba1c ≤8.5% * willing to follow diet counseling and maintain a stable low-fat diet * must be on standard of care lipid-lowering medications per local guidelines (unless documented as intolerant as determined by the investigator) exclusion criteria: * use of any hepatocyte-targeted small interfering ribonucleic acid (sirna) that targets lipids and/or triglycerides within 365 days before day 1 (except inclisiran, which is permitted). administration of investigational drug and inclisiran must be separated by at least 4 weeks. * use of any other hepatocyte targeted sirna or antisense oligonucleotide molecule within 60 days or within 5-half-lives before day 1 based on plasma pharmacokinetics (pk), whichever is longer * acute pancreatitis within 4 weeks prior to screening * body mass index \>45 kg/m\^2 note: additional inclusion/exclusion criteria may apply per protocol